From GlobeNewswire: 2024-04-03 11:30:00

The intestinal pseudo-obstruction treatment market has seen strong growth, with a projection to reach $24.98 billion in 2024. Factors contributing to this growth include the rise in chronic respiratory diseases, patient preference, pediatric applications, and market expansion in allergic rhinitis treatment.

The market is expected to continue growing and reach $30.87 billion by 2028, driven by factors like the increasing geriatric population, global respiratory issues, and advancements in formulation technologies. Innovations in pediatric and geriatric applications, self-administration devices, and biologics are anticipated trends.

Parkinson’s disease is expected to further boost the intestinal pseudo-obstruction treatment market due to its impact on the central nervous system. Increased PD diagnoses in the US highlight the need for effective treatment options to address non-motor symptoms like constipation and intestinal pseudo-obstruction.

Key players in the market, such as Pfizer and Johnson & Johnson, are developing novel drug therapies like NHE3 inhibitor treatments to meet patient needs. Strategic acquisitions aim to enhance innovation pipelines, with a focus on improving gastrointestinal motility and redefining care standards for GI patients.



Read more at GlobeNewswire: Robust Growth Expected In The Intestinal Pseudo Obstruction